top of page

Therapeutic capabilities
Carrying endogenous therapeutic cargo

Targeting ability
Homing ability to tumor sites

Robust and multi faceted
Can be combined with exogenous therapies

Protecting cargo
Minimal degradation in body fluids and circulation

Non-Immunogenic
Low expression of MHC class I and class II – "off the shelf" products

Enhanced stability
Stable in body fluids, easy to store, handle, and administer

Prolonged PK/PD profile
superior to other delivery systems (liposomes, nanoparticles)

Safety
Cellular sources demonstrated safety in multiple pre-clinical studies and clinical trials

High batch reproducibility
AI-based real-time controlled EV production process

EviCure's Advantages
For Targeted Cancer Therapy

EviCure’s EV Advantages
For targeted cancer therapy
bottom of page